Polygiene Group AB

Polygiene maintains a strong liquidity position with a current ratio of 5.08 and cash and equivalents of 54.28 million SEK, representing 16.4% of total assets. The company's price-to-book ratio of 0.7 and price-to-tangible-book ratio of 0.7 indicate a significant discount to net asset value, while the debt-to-equity ratio of 0.01 shows minimal leverage. The company reported a net loss of 745,000 SEK for the period, with a negative return on equity of -0.24% and return on assets of -0.23%. These metrics fall below the typical performance benchmarks for specialty chemicals firms, which usually maintain positive ROE above 10% and ROA above 5%. Polygiene operates as a single-segment business with 100% revenue concentration in its core antimicrobial solutions. The company's geographic exposure is not disclosed in the available data, but its market capitalization of 215.5 million SEK suggests limited international scale compared to global specialty chemicals peers. Analysts project a significant revenue increase to 175 million SEK for the current fiscal year, representing a 16.4% year-over-year growth from the 150.35 million SEK reported in the latest period. However, the company's negative net income of -0.15 SEK per share contrasts sharply with the 0.71 SEK mean EPS estimate. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's free cash flow of 321,000 SEK and capital expenditures of -802,000 SEK suggest modest reinvestment activity. Recent analyst estimates show consensus price targets of 22.00 SEK, implying a 272% upside from the current market price of 5.9 SEK. This wide valuation gap reflects either significant growth expectations or potential mispricing in the current market.